User Tools

Site Tools


thrombolysisami

thrombolysis for AMI

thrombolytic therapy for AMI's:

indications for coronary reperfusion:

  • NB. if coronary re-perfusion is indicated, percutaneous coronary intervention (primary PCI or “hot angioplasty”) is usually the preferred option if available within 2 hours
  • NB. acute AMI warranting emergency coronary re-perfusion Rx defined as:
    • chest pain consistent with ischaemia lasting > 20mins, not relieved by S/L nitrates, and,
    • ECG criteria:
      • ST elevation >= 2mm in >= 2 contiguous chest leads, or,
      • ST elevation >= 1mm in >= 2 contiguous limb leads, or,
      • new LBBB
  • NB. resolution of pain does NOT mean that coronary re-perfusion is no longer indicated!!!!
  • coronary re-perfusion should still be considered as long as ECG criteria persist and time since onset of pain is still within criteria
  • NB. coronary re-perfusion should still be considered in pts with evolving infarcts up to 24hrs from onset of chest pain if there is evidence of on-going ischaemia
    • ie. ongoing chest pain with ST elevation
    • coronary re-perfusion in this circumstance is based on risk vs benefit for individual patient
    • benefit greatest if anterior AMI & those with evidence of cardiac failure

TPA vs PCI when re-perfusion is indicated:

  • depends upon consideration of:
    • time from onset of symptoms
    • risk of complications from STEMI
    • risk of bleeding from thrombolysis - see thrombolytics
    • time to transfer to a cath lab
  • consider thrombolysis (aim to give within 30min of arrival) if no C/I and:
    • onset of pain is within 12 hours AND delay to PCI > 2hrs, or,
    • onset of pain 12-24hrs with continued pain or ECG changes AND PCI unavailable

indications for transfer to PCI after thrombolysis:

  • cardiogenic shock or acute severe cardiac failure
  • failed re-perfusion or re-occlusion
  • as part of an invasive strategy in stable patients for PCI 3-24hrs after thrombolysis

limitations to thrombolytic Rx for AMI's:

  • limited applicability - only 15-25% eligible
  • failure to achieve infarct-related artery patency (15-40%)
  • presence of high grade stenosis after successful thrombolysis (75-80%)
  • immediate re-occlusion & recurrent ischaemia (15-20%)
  • serious bleeding complications: 0.5-1.0% risk of haemorrhagic stroke
  • poor results in certain subgroups:
    • those with increased risk of bleeding
    • elderly
    • cardiogenic shock
    • previous bypass graft surgery

failed coronary thrombolysis:

  • seminar article in Lancet April 18, 1998 vol 351(9110)
  • the only indicators that are of some use in early detection of successful thrombolysis is:
    • abrupt cessation of chest pain predicts reperfusion
      • sens. 66-84%, spec. < 30%
      • only occurs in 30-50% of pts
    • resolution of ST elevation on 12 lead ECGs at 40min & 120min after commencement of thrombolysis
      • 25-50% fall either in:
        • sum of all leads with ST elevation, or,
        • single worst lead
      • sensitivity 52-97%, spec. 43-88%
      • 30day mortality rates: <30% fall in ST ⇒ 18%; 30-70% fall ⇒ 5%; > 70% fall ⇒ 2.5%
  • other indicators of successful thrombolysis are:
    • CK-MB peak on 1st day - wash-out effect
    • reperfusion arrhythmias

aetiology & potential Mx:

  • TIMI flow grades:
    • 0 & 1: angiographic occlusion
    • 2: impaired flow
    • 3: angiographically normal flow
  • TIMI 3 flow is achieved in only 31% pts with SK and 54% pts with tPA, thus substantial proportion of pts have suboptimal result which may be due to:
    • failure of epicardial reperfusion:
      • inability to achieve lytic state
        • in pts given SK, this may be indicated by:
          • inadequate reduction of fibrinogen levels
          • raised levels of thrombin/antithrombin III complexes
        • this may be addressed with repeat thrombolysis but:
          • additional risk of intracranial h'age - presumably a summation of previous risk ie. now 0.94% rather than 0.49% as inferred from SK vs SK + tPA in GUSTO-1
          • cannot easily detect failed lytic state thus would Rx many who would not benefit
      • mechanical factors at fissured plaque
        • this may be addressed by:
          • rescue angioplasty but this is usually delayed and thus has not been shown to be of benefit
          • intra-aortic balloon pumping has been shown to improve both vessel patency & LV function
            • this has a role in the hypotensive pt with cardiogenic shock
    • failure of microcirculatory perfusion (“no reflow”):
      • early:
        • associated with capillary occlusion with platelet microthrombi which are resistant to thrombolytic agents, which may paradoxically increase platelet reactivity & thrombin activity
        • can this be addressed by intensified antiplatelet Rx:
          • abciximab
      • late:
        • due to loss of microvascular integrity due to endothelial & myocardial oedema which is partly mediated by oxygen radical injury at the time of reperfusion, esp. if there is delay in thrombolysis
  • conclusions:
    • failure of ST segment resolution in a pt with:
      • limited infarction (ST elevation in 5 or less leads) & who is haemodynamically stable should be Mx conservatively since this is a low risk group.
      • hypotension & cardiogenic shock should be considered for immediate angioplasty even if this requires transfer to another centre.
      • ST elevation in 6 or more leads & continuing ischaemic chest pain then either repeat thrombolysis or rescue angioplasty (according to availability) seem justifiable.
        • early signs of haemodynamic instability (tachycardia or falling BP) should lower threshold for action
        • if angioplasty undertaken, adjunctive Rx may be required:
          • intra-aortic balloon pumping
          • abciximab
thrombolysisami.txt · Last modified: 2014/11/05 10:16 by 127.0.0.1

Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki